找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Kala Azar in South Asia; Current Status and S E. Noiri,T.K. Jha Book 2016Latest edition Springer International Publishing 2016 Neglected Tr

[復制鏈接]
樓主: Malicious
31#
發(fā)表于 2025-3-26 23:28:14 | 只看該作者
http://image.papertrans.cn/k/image/541720.jpg
32#
發(fā)表于 2025-3-27 04:54:16 | 只看該作者
33#
發(fā)表于 2025-3-27 08:30:17 | 只看該作者
linical, epidemiological and entomological aspects.Includes .Visceral leishmaniasis (VL), (also known as black fever or Kala-azar) is a life-threatening disease?first reported from the Indian subcontinent. VL ranks as the world’s second largest parasitic disease killer and is a neglected tropical di
34#
發(fā)表于 2025-3-27 10:07:26 | 只看該作者
35#
發(fā)表于 2025-3-27 14:47:47 | 只看該作者
36#
發(fā)表于 2025-3-27 20:43:45 | 只看該作者
Vaccine Development for Leishmaniasisalian hosts, enabling a multilateral prevention strategy. Furthermore, the use of a vaccine is now not only for prevention but also for treatment. Within this manuscript we review background information, the current status, and the future direction of vaccine development for leishmaniasis.
37#
發(fā)表于 2025-3-27 23:53:48 | 只看該作者
Potentiality of Urinary L-FABP Tests to Kala-Azar Disease Managementrinary immuno-chromatography dipstick test for point of care use in endemic areas. We expect that a FABP1 dipstick test will serve as a triage marker in disease monitoring of VL. In addition, this chapter introduces the impact of FABP1 on predicting survival in septic acute kidney injury and the clinical interpretation of FABP1 measurements in VL.
38#
發(fā)表于 2025-3-28 04:42:45 | 只看該作者
39#
發(fā)表于 2025-3-28 09:04:20 | 只看該作者
40#
發(fā)表于 2025-3-28 12:11:39 | 只看該作者
Changes of , Antigens in Kala-Azar Patients’ Urine After Treatment than that with nested PCR (88 %), but higher than that with KAtex (48 %) before the treatment, and it reduced more slowly than that with the others after the treatment. As the urine ELISA gives CA levels quantitatively, it will be useful to evaluate the efficacy of the treatments used and for surveillance of drug resistance.
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 11:14
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
乐陵市| 宜城市| 泗水县| 邢台县| 两当县| 九寨沟县| 秭归县| 确山县| 温州市| 来安县| 北京市| 平塘县| 吴江市| 碌曲县| 宜城市| 罗甸县| 张家港市| 大关县| 东乌珠穆沁旗| 驻马店市| 科尔| 栖霞市| 元阳县| 蓝田县| 九寨沟县| 肃南| 江油市| 陵水| 延寿县| 临武县| 中江县| 轮台县| 灯塔市| 东阿县| 井冈山市| 泌阳县| 繁峙县| 嵊州市| 乌审旗| 布尔津县| 志丹县|